Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV single-arm study of BIMERVAX XFG.1.1 booster safety and immunogenicity against SARS-CoV-2 Omicron XFG.1.1
2026-527363-16-00Phase 4Completed
- Sponsor
- HIPRA
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of PHH-1V in coronavirus disease 2019 (COVID-19), sponsored by HIPRA. Primary endpoints: Solicited local and systemic reactogenicity through Day 7, Unsolicited adverse events and 5 more. Started Sep 2026; status: completed.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2026-527363-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527363-16-00.